One of the most exciting areas in all of medicine is rooted in the understanding of Regenerative Biologics. The Mechanism Of Action (MOA) as it pertains to the various product options in this category is the same across the board: paracrine signaling, or “cell-to-cell communication,” is the most important function that these novel products produce. Whether you are considering Platelet Rich Plasma (PRP) and/or concentrated Bone Marrow Aspirate (cBMA) from a fully enclosed and sterile processing system, or minimally manipulated DMSO-free cryogenically preserved human birth tissue allografts derived from the umbilical cord, we have the experience and knowledge to guide you through the process of selecting the correct option for your practice.

There is a vast and growing amount of studies from around the world in nearly all verticals of medicine that demonstrate both efficacy and safety with these products, and while the FDA has not approved these products for very many applications there is an ever-growing community of Physicians and Researchers alike that are eager to share information about the promise of this field.

As a manufacturer’s representative, we are unable to address any information about applications and outcomes related to the following items:

  • Stem Cell therapy
  • Exosome therapy (specifically bio-engineered products, not relevant to the incidental and inconsequential “exosomal” aesthetic products discussing topical use)
  • Applications for any HCT/p product, as these products do not have pre-market approval and as such do not have any defined application/indication

We pride ourselves in compliance and education, and as such we are happy to direct you to studies relevant to your interests and engage in educational discussions surrounding the legal landscape (specifically as it pertains to the FDA’s views and regulations on marketing these products).

Send us your contact  below for more information!



    The MAGELLAN® is an autologous concentration system that delivers concentrated platelets and cells at the point of care.

    Fully Automated

    Simple one-button start for ease of use


    Closed System

    Minimal breaks in sterile barrier promote safety


    BioAdaptive Processing

    Works with optical sensors to tailor processing parameters based on each patient’s hematocrit


    Optical Sensors

    Identify the cellular fraction to eliminate error and optimize results


    Selectable Output

    Allows users to define desired therapeutic volumes (3-10 mL per cycle)